We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Corgenix Cancels Genesis Bioventures Merger

By Labmedica staff writers
Posted on 08 Feb 2005
Due to a lack of progress toward the completion of the financing and the expiration dates on legal documents, Corgenix Medical Corp (Denver, CO, USA) has terminated its proposed U.S.$6 million merger with Genesis Bioventures (Surrey, Canada).

Corgenix develops and manufactures anti-phospholipid test kits, and its anticardiolipin (aCL) assay has been cleared by the U.S. More...
Food and Drug Administration (FDA). The company is focused on the development of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

"We regret that it was necessary to terminate the proposed merger after spending so much time and energy on it,” stated Douglass Simpson, president of Corgenix. "However, on the positive side, Corgenix is investigating a broad range of business opportunities, including the pursuit of our own equity financing.”





Related Links:
Corgenix
Genesis Bioventures

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.